



Business Spectator

NEWS

12:39 PM, 3 Jun 2009

Molecular Discovery collaborates on Floppy Baby syndrome screening


Source: News Bites

BioPharmica Ltd announced on June 2 that subsidiary Molecular Discovery Systems' research scientist Rachel Ramsdale is collaborating with the Laing Neuromuscular Diseases Group to screen medications that might increase cardiac actin in skeletal muscles.

This potentially offers a treatment for patients born with Floppy Baby Syndrome, a congenital myopathy disorder that causes babies to be born without the ability to properly use their muscles.

This follows a world first, where West Australian scientists cured mice of the disease, as recently published in the "Journal of Cell Biology".

Molecular Discovery's main business, since launching in 2006, is drug discovery and the validation of biomarkers for disease, therapy and diagnostics.



<http://www.businessspectator.com.au/bs.nsf/Article/Molecular-Discovery-collaborates-on-Floppy-Baby-sy-SN56X?OpenDocument>